Medical Statistics has never been easier!

David E. Matthews
Vernon T. Farewell

Using and Understanding Medical Statistics
5th, revised and extended edition

The fifth revised edition of this highly successful book presents the most extensive enhancement since Using and Understanding Medical Statistics was first published 30 years ago. Without question, the single greatest change has been the inclusion of source code, together with selected output, for the award-winning, open-source, statistical package known as R. This innovation has enabled the authors to de-emphasize formulae and calculations, and let software do all of the 'heavy lifting'.

This edition also introduces readers to several graphical statistical tools, such as Q-Q plots to check normality, residual plots for multiple regression models, funnel plots to detect publication bias in a meta-analysis and Bland-Altman plots for assessing agreement in clinical measurements. New examples that better serve the expository goals have been added to a half-dozen chapters. In addition, there are new sections describing exact confidence bands for the Kaplan-Meier estimator, as well as negative binomial and zero-inflated Poisson regression models for over-dispersed count data.

The end result is not only an excellent introduction to medical statistics, but also an invaluable reference for every discerning reader of medical research literature.

Contents
Preface to the Fifth Edition
Prefaces to the Previous Editions
• Basic Concepts
• Tests of Significance
• Fisher’s Test for 2 × 2 Contingency Tables
• Approximate Significance Tests for Contingency Tables
• Some Warnings concerning 2 × 2 Tables
• Kaplan-Meier or ‘Actuarial’ Survival Curves
• The Log-Rank or Mantel-Haenszel Test for Comparing Survival Curves
• An Introduction to the Normal Distribution
• Analyzing Normally Distributed Data
• Linear Regression Models for Medical Data
• Binary Logistic Regression
• Regression Models for Count Data
• Proportional Hazards Regression
• The Analysis of Longitudinal Data
• Analysis of Variance
• Data Analysis
• The Question of Sample Size
• The Design of Clinical Trials
• Further Comments regarding Clinical Trials
• Meta-Analysis
• Epidemiological Applications
• Diagnostic Tests
• Agreement and Reliability

References

Subject Index

Matthews, D.E. (Waterloo, Ont.);
Farewell, V.T. (Cambridge)

Using and Understanding Medical Statistics
5th, revised and extended edition

X + 338 p., 48 fig., 103 tab., 2015
CHF 49.00 / EUR 46.00 / USD 54.00
(hard cover + online supplementary material)

Online version for institutional purchase
Prices subject to change, VAT not included
EUR price for eurozone countries, USD price for USA and Latin America only
(hard cover + online supplementary material)

eBook available on:
Google play
amazon
VitalSource

Dear Librarian
I have reviewed this publication and would like to recommend it for our library
Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Karger – Medical and Scientific Publishers
CH–4009 Basel, Switzerland
orders@karger.com, F +41 61 306 12 34
www.karger.com

KI 15406
Editor-in-Chief
G. Minotti, Rome

Associate Editors
G. Delogu, Rome
G. Graziani, Rome

Editorial Board
A.M. Biroccio, Rome
C. Chiesa, Rome
S. Gemma, Siena
S. Horkovics-Kovats, Kundl
S. Kohno, Nagasaki
C. Landersdorfer, Parkville, Vic.
P. Linder, Geneva
K. Machka, Munich
P. Menna, Rome
E. Monti, Busto Arsizio
K.G. Naber, Straubing
R. Nau, Göttingen
P. Preziosi, Rome
E. Salvatorelli, Rome
M. Sanguinetti, Rome
G. Sava, Trieste
G.M. Shah, Quebec, Que.
F. Sörgel, Nuremberg-Heroldsberg
J.C. Stingl, Bonn
F. Van Bambeke, Brussels
M. Wilhelm, Nuremberg

The founder of chemotherapy
Paul Ehrlich
1854–1915

International Journal of Experimental and Clinical Chemotherapy
Founded 1959 as “Chemotherapia” by H.P. Kuenmerle and P. Rentchnick
Guidelines for Authors

Submission
Before submission, please read the Guidelines for Authors for specific requirements for manuscript preparation. Manuscripts written in English are considered and should be submitted online at www.karger.com/che (a link leads you to the Submission Website).

Submission of an article implies author agreement with the below Conditions. To be considered for publication, all manuscripts must be accompanied by a cover letter signed by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission.

A Copyright Transfer Form, available on the Submission Website, with the corresponding author’s original (handwritten) signature must be received by the editorial office. Please print and sign the form, and upload it during submission (or fax or scan and email) to make it legally binding.

Names, postal and e-mail addresses of 4 international experts in the appropriate area of research should accompany each manuscript. At the Editors’ discretion, discretion decision(s) selected from this list may be invited to act as referee(s). Referees suggested should not be from the same institution as the author.

Presentation of manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (April 2010 version). Available from: http://www.ICMJE.org).

In case of problems with submission, please contact:
che@karger.com
S. Karger AG – Medical and Scientific Publishers
Editorial Office “Chemotherapy”
Allschwilerstrasse 10
CH-4099 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434

Conditions
All manuscripts are subject to editorial and peer review. Manuscripts are received with the explicit understanding that the work has not been published (wholly or in part), and is not under simultaneous consideration in any language elsewhere. Furthermore, all authors have made substantial contributions and confirm that they have seen and approved the manuscript submission. Submission of an article for publication implies the transfer of the copyright from the author to Karger Publishers upon acceptance. Accepted papers become the permanent property of Chemotherapy and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflict of Interest
Authors are required to disclose any sponsorship or funding arrangements related to the research presented in the manuscript and any possible conflicts of interest. A possible conflict of interest does not preclude consideration of a manuscript for publication, but the Editor might consider it appropriate to publish the disclosed information with the paper. All forms of support and financial involvement should be listed in the Acknowledgements section of the paper. The cover letter should certify that all forms of conflict of interest by all authors were clearly identified and should be arranged in the same way as full length manuscripts (maximum 1,600 words).

Letters to the Editor: Letters to the Editor are encouraged if they directly concern articles recently published in this journal. Authors are invited to submit such letters to the authors of the articles concerned prior to publication in order to allow them to respond in the same issue of the journal. In exceptional cases, Letters to the Editor may also address data published in another journal or general subjects related to matters discussed in the journal. No abstract is required (maximum 1,200 words).

Arrangement
The preferred word processing program is MS-Word. The cover letter, the manuscript, the tables and the figures must be submitted in separate files. The manuscript file must contain all the text elements in the following order: title page, abstract and key words, main text, acknowledgments, references, table and figure legends. Tables and figures should be submitted as separate files according to the instructions below. Automatic line numbering should be used consecutively from the title page through to the final page. All pages should be numbered, starting from the title page, including tables, figure legends and figures.

Title page: The first page should contain the concise title of the article along with a short title for use as a running head, the full names of the authors and their affiliations (department, institute, hospital, university etc. where the work was conducted). The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Key words: Please supply 3–10 key words that reflect the content of the paper.

Abstract: Each original paper needs an abstract of up to 250 words structured with subheadings as follows: Background/aims, Methods, Results, Conclusions. Structured abstracts are not needed for Reviews and Novel Insights from Clinical Practice.

Footnotes: Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgments: Include all sources of funding for the research presented in the manuscript and substantive contributions of individuals regarding the research or manuscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained when they are first used.

Units of measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lowercase) whenever possible. Registered trade names (first letter: uppercase) should be marked with the superscript registration symbol ® or ™ when they are first mentioned.

Tables and illustrations: Tables and figures must be numbered (e.g. Figure 1, Figure 2) and submitted as separate files. Tables require a heading and figures a legend, which must provide sufficient information for either to stand alone. Each figure and table must be cited in the text numerically. Tables should be in Word format. b/w half-tone and color figures must have a final resolution of 300 dpi after scaling to final size, line drawings 1,200 dpi. Color figures must be in RGB format. All figures should be in a common format such as PSD, TIF, PNG, EPS or WMF. Vector graphics should be in PPT, AI or EPS format.
Color Illustrations
Online edition: Color figures are reproduced free of charge. In the print version, the figures are reproduced in black and white. Reprinting colors in the text and figure legends should be avoided.

Print edition: Up to 6 color figures per page can be integrated within the text at CHF 960.00 per page.

References
Identify references in the text using Arabic numerals [in square brackets]. Do not alphabetize; number references sequentially in the order cited in the text. Material submitted for publication but not yet accepted should be referred to as [unpublished data] and should not be included in the reference list. The reference list should include only those publications which are cited in the text. Authors’ surnames should be followed by their initials with no punctuation other than a comma to separate individual authors. Preferably cite all authors (if not possible include at least 3 authors followed by et al). Abbreviate journal names according to the list of journals indexed for MEDLINE on the NLM website. Also see International Committee of Medical Journal Editors: Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.ICMJE.org).

Examples


Reference Management Software: The use of EndNote is recommended to facilitate formatting of citations and reference lists. The journal output style can be downloaded from http://endnote.com/downloads/styles.

Supplementary Material and Multimedia Files
Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 Mb in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.

English Language Editing
For authors whose native language is not English, use of a professional language editing service prior to submission can help to avoid delays with the review process.

Digital Object Identifier (DOI)
A DOI number will be available as a unique identifier on the title page of each article. DOIs are useful for identifying and citing articles published online without volume or issue information (for more information, see www.doi.org).

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:
- Be used for noncommercial purposes only
- Be linked to the final version on www.karger.com
- Include the following statement:
  “This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/doi-10.1159/000361001.”

It is the author’s responsibility to fulfill these requirements. Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf (see Funding Organizations (NIH etc.)).

For self-archiving Author’s Choice™ (Gold Open Access) articles, see Author’s Choice™.

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:
- Follow the terms of the relevant Creative Commons license
- Be linked to the final version on www.karger.com
- Include the following statement:
  “The final, published version of this article is available at http://www.karger.com/doi-10.1159/000361001.”

It is the author’s responsibility to fulfill these requirements.

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Copy Editing
Manuscripts accepted for publication by Karger Publishers are subject to copy editing.

Proofs
An email containing a link to download the proofs will be sent to the corresponding author. Proofs should be returned within 48 hours. Alterations made in proofs, other than the correction of printer’s (introduced) errors, are charged to the author and may require editorial approval.

Page Charges
There is no page charge for papers of 3 or fewer printed pages (including tables, illustrations and references). Authors are charged CHF 325.00 for each additional complete or partial printed page.

Reprints
An order form with a price list can be requested when returning the corrected proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

© 2017 S. Karger AG, Basel

The Guidelines for Authors are available at:
www.karger.com/che_Guidelines
Contents

See the journal website for contents
The first oncology journal dedicated exclusively to case reports

Case Reports in Oncology

www.karger.com/cro

- open access
- peer-reviewed
- fast online publication

This peer-reviewed online-only journal publishes original case reports covering the entire spectrum of oncology, including prevention, diagnosis, treatment, toxicities of therapy, supportive care, quality-of-life, and survivorship issues. The journal will also accept case reports dealing with the use of novel technologies, both in the arena of diagnosis and treatment. Supplementary material is welcomed. The intent of the journal is to provide clinicians and researchers with a tool to disseminate their personal experiences to a wider public as well as to review interesting cases encountered by colleagues all over the world. Universally used terms can be searched across the entire growing collection of case reports, further facilitating the retrieval of specific information.

Following the open access principle, the entire contents can be retrieved at no charge, guaranteeing easy access to this valuable source of anecdotal information at all times.
Antimicrobial Section

Original Papers

231 Anaemia following Artemisinin-Based Combination Treatments of Uncomplicated Plasmodium falciparum Malaria in Children: Temporal Patterns of Haematocrit and the Use of Uncomplicated Hyperparasitaemia as a Model for Evaluating Late-Appearing Anaemia
Sowunmi, A. (Abuja/Ibadan); Akano, K. (Ibadan); Ntadom, G. (Abuja); Ayede, A. (Ibadan); Oghuche, S. (Abuja/Jos); Agomo, C. (Abuja/Lagos); Okafor, H. (Abuja/Enugu); Watila, I. (Abuja/Maiduguri); Meremikwu, M. (Abuja/Calabar); Ogala, W. (Abuja/Zaria); Agomo, P. (Abuja/Lagos); Adowoye, E. (Ibadan); Fatunmbi, B. (Phnom Penh); Aderoyeje, T. (Ibadan); Happi, C. (Abuja/Ede); Gbotosho, G. (Ibadan); Folarin, O. (Ede)

256 Ten-Year Trends and Clinical Relevance of the Antimicrobial Resistance Genotype in Respiratory Isolates of Streptococcus pneumoniae

262 An Uncommon ST1224 NDM-1-Producing Klebsiella pneumoniae Isolated from the Bloodstream of a Leukemia Patient in China

Anticancer Section

Original Papers

205 Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy
Kotake, M. (Shibukawa); Miura, Y.; Imai, H. (Ohta); Mori, K. (Shizuoka); Sakurai, R. (Shibukawa); Kaira, K. (Maebashi); Tomizawa, Y. (Shibukawa); Minato, K. (Ohta); Saito, R. (Shibukawa); Hisada, T. (Maebashi)

214 Expanding the Role of Chloroquine as a Potent Antineoplastic Agent in Different Gastrointestinal Malignancies
Kapoor, S. (Atlanta, GA)

215 Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen
Naito, M.; Yamamoto, T.; Shimamoto, C.; Miwa, Y. (Osaka)

225 Dynamics of L-Carnitine in Plasma and Urine in Patients Undergoing Cisplatin Chemotherapy

239 Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents
Kogo, M.; Sunaga, T.; Nakamura, S. (Tokyo/Kanagawa); Akita, T. (Uokohama); Kurihara, T. (Tokyo/Kanagawa); Shikama, Y.; Nakajima, H. (Tokyo); Tobe, T. (Uokohama); Yoneyama, K. (Tokyo); Kiuchi, Y. (Uokohama)

246 Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase Ila in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy

Letter to the Editor

214 Expanding the Role of Chloroquine as a Potent Antineoplastic Agent in Different Gastrointestinal Malignancies
Kapoor, S. (Atlanta, GA)